ImmunoTargets and Therapy

CombImmunoTherapy: Personalizing Oncology Treatment

In 2011, the first immunotherapy for cancer was approved. Since then, the FDA has approved at least 11 immune checkpoint inhibitors and other types of immunotherapies, including CAR T-cell therapies. Currently, there are more than 1,000 immunotherapy clinical trials underway across the United States alone, with 15-20% of patients experiencing robust results. While immunotherapy has significant promise, traditional methods of cancer treatment, such as chemotherapy and radiation therapy, still prevail as the first line of treatment. As we learn more about factors such as the tumor microenvironment that influence treatment efficacy, one thing remains clear – there is a great need for personalized combination therapy. CIT provides a more tailored approach, allowing oncologists flexibility to effectively treat each individual patient.